Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

被引：9
|
作者：
Chi, Y. [1 ]
Gao, M. [2 ]
Zhang, Y. [3 ]
Shi, F. [4 ]
Cheng, Y. [5 ]
Guo, Z. [6 ]
Ge, M. [7 ]
Qin, J. [8 ]
Zhang, J. [9 ]
Li, Z. [10 ]
Zhou, X. [11 ]
Huang, R. [12 ]
Chen, X. [13 ]
Liu, H. [14 ]
Cheng, R. [15 ]
Xu, Z. [16 ]
Zheng, X. [2 ]
Li, D. [2 ]
Tang, P. [17 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Oncol, Tianjins Clin Res Ctr Canc, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin, Peoples R China
[3] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Head & Neck Surg Dept,Jiangsu Canc Hosp, Nanjing, Peoples R China
[4] Hunan Canc Hosp, Nucl Med Ctr, Thyroid Tumour Internal Med Dept, Changsha, Peoples R China
[5] Jilin Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Head & Neck Surg, Guangzhou, Peoples R China
[7] Chinese Acad Sci, Head & Neck Surg Inst Canc & Basic Med ICBM, Canc Hosp,Univ Chinese Acad Sci,Zhejiang Canc Hos, Zhejiang Prov Peoples Hosp,Peoples Hosp,Hangzhou, Hangzhou, Peoples R China
[8] Zhengzhou Univ, Affiliated Canc Hosp, Thyroid & Head & Neck Surg, Henan Canc Hosp, Zhengzhou, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Thyroid Surg Ward, Harbin, Peoples R China
[10] China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Dept Head & Neck Surg, Shenyang, Peoples R China
[11] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Head & Neck Surg, Chongqing, Peoples R China
[12] Sichuan Univ, West China Hosp, Nucl Med, Chengdu, Peoples R China
[13] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China
[14] Fujian Canc Hosp, Head & Neck Dept, Fuzhou, Peoples R China
[15] Kunming Med Univ, Affiliated Hosp 1, Dept Thyroid Surg, Kunming, Yunnan, Peoples R China
[16] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Head & Neck Surg,Natl Canc Ctr, Beijing, Peoples R China
[17] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept VIP,Natl Canc Ctr, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA88
引用
收藏
页码：S1215 / S1215
页数：1
相关论文
共 50 条
  • [31] Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
    Marcia S Brose
    Christopher M Nutting
    Steven I Sherman
    Young Kee Shong
    Johannes WA Smit
    Gerhard Reike
    John Chung
    Joachim Kalmus
    Christian Kappeler
    Martin Schlumberger
    BMC Cancer, 11
  • [32] Efficacy and safety of second-line treatment with surufatinib for anlotinib-resistant radioiodine-refractory differentiated thyroid cancer: An exploratory multicenter study
    Wang, Yang
    Qiu, Zhongling
    Wang, Xufu
    Han, Na
    Li, Jiao
    Zhai, Hongyan
    Zhou, Zhenhu
    Gao, Rui
    Ji, Ting
    Chen, Libo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial
    Brose, Marcia S.
    Worden, Francis P.
    Newbold, Kate L.
    Guo, Matthew
    Hurria, Arti
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2692 - +
  • [34] A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
    Chen, Jiaying
    Ji, Qinghai
    Cao, Junning
    Ji, Dongmei
    Bai, Chunmei
    Lin, Yansong
    Pan, Bin
    Sun, Guofang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial (vol 30, pg 134, 2012)
    Wells, S. A., Jr.
    Robinson, B. G.
    Gagel, R. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) : 3049 - 3049
  • [36] A multicenter phase II of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullar thyroid carcinoma: Mature data of THYSU study
    De la Fouchardiere, C.
    Delord, J. P.
    De Bazignan, A. Doussau
    Catargi, B.
    Docao, C.
    Asselineau, J.
    Picat, M. Q.
    Rodien, P.
    Pouessel, D.
    Nicolli-Sire, P.
    Klein, M.
    Bournaud-Salinas, C.
    Caron, P.
    Wemeau, J. L.
    Gimbert, A.
    Sitta, R.
    Digue, L.
    Ravaud, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S576 - S576
  • [37] Vandetanib (VAN) in locally advance or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA)
    Wells, S. A.
    Robinson, B. G.
    Gagel, R. F.
    Dralle, H.
    Fagin, J. A.
    Santoro, M.
    Baudin, E.
    Vasselli, J. R.
    Read, J.
    Schlumberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial
    Chen, Jiaying
    Ji, Qinghai
    Bai, Chunmei
    Zheng, Xiangqian
    Zhang, Yuan
    Shi, Feng
    Li, Xiaojiang
    Tang, Pingzhang
    Xu, Zhengang
    Huang, Rui
    Huang, Tao
    Pan, Yueyin
    Fan, Songhua
    Zhou, Jinghong
    Su, Weiguo
    THYROID, 2020, 30 (09) : 1245 - 1253
  • [39] A Phase 2 Trial of Lenvatinib (E7080) in Advanced, Progressive, Radioiodine-Refractory, Differentiated Thyroid Cancer: A Clinical Outcomes and Biomarker Assessment
    Cabanillas, Maria E.
    Schlumberger, Martin
    Jarzab, Barbara
    Martins, Renato G.
    Pacini, Furio
    Robinson, Bruce
    McCaffrey, Judith C.
    Shah, Manisha H.
    Bodenner, Donald L.
    Topliss, Duncan
    Andresen, Corina
    O'Brien, James P.
    Ren, Min
    Funahashi, Yasuhiro
    Allison, Roger
    Elisei, Rossella
    Newbold, Kate
    Licitra, Lisa F.
    Sherman, Steven I.
    Ball, Douglas W.
    CANCER, 2015, 121 (16) : 2749 - 2756
  • [40] Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
    Haugen, Bryan
    French, Jena
    Worden, Francis P.
    Konda, Bhavana
    Sherman, Eric Jeffrey
    Dadu, Ramona
    Gianoukakis, Andrew G.
    Wolfe, Eric G.
    Foster, Nathan R.
    Bowles, Daniel W.
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345